Table 3.

Cure rates and missing patients in the all-treated target and clinically evaluable populations

	Telavancin	Standard therapy	95% CI for the difference (telavancin–standard therapy)
	n/N (%)	n/N (%)
All-treated target
End-of-therapy visit	11/15 (73%)	15/16 (94%)	(–44.4, 7.8)
Follow-up visit	9/15 (60%)	14/16 (88%)	(–53.6, 4.5)
Test-of-cure visit	8/15 (53%)	11/16 (69%)	(–45.9, 18.5)
Clinically evaluable
End-of-therapy visit	8/8 (100%)	9/9 (100%)	(–26.1, 24.3)
Follow-up visit	7/8 (88%)	9/9 (100%)	(–41.0, 19.1)
Test-of-cure visit	7/8 (88%)	8/9 (89%)	(–35.5, 31.9)
MRSA	5/5 (100%)	4/4 (100%)	-
MSSA	2/3 (67%)	4/5 (80%)	-

CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.